Pentazocine, besides having analgesic properties, also has a stimulatory effect on the cardiovascular system. This latter effect has been demonstrated in patients undergoing treatment for myocardial infarction. A rise in both systemic and pulmonary vascular pressures and in cardiac output has been shown clinically. There is conflicting evidence as to the possible mode of action of this drug, since it has been shown by Levitsky et al. (1971) that the drug acts directly on the adrenergic beta receptors in intact dogs, but by Tammisto et al. (1971) that in human volunteers it acts on the adrenergic beta receptors indirectly; a marked rise in catecholamines in the blood could be demonstrated in the volunteers after the drug was given.
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Effects of Pentazocine on Cardiac Function
Pentazocine, besides having analgesic properties, also has a stimulatory effect on the cardiovascular system. This latter effect has been demonstrated in patients undergoing treatment for myocardial infarction. A rise in both systemic and pulmonary vascular pressures and in cardiac output has been shown clinically. There is conflicting evidence as to the possible mode of action of this drug, since it has been shown by Levitsky et al. (1971) that the drug acts directly on the adrenergic beta receptors in intact dogs, but by Tammisto et al. (1971) that in human volunteers it acts on the adrenergic beta receptors indirectly; a marked rise in catecholamines in the blood could be demonstrated in the volunteers after the drug was given.
Evidence becomes more conflicting when the results of in vitro experiments are considered. A dose-dependent depressant effect has been demonstrated in isolated cat capillary muscle and the rabbit heart; but in these experiments the concentrations used were often far in excess of those found clinically by Berkowitz et al. (1969) .
We have found pentazocine interesting because of this dual effect. It is also related to nalorphine and is therefore a morphine antagonist. Further in vitro studies have been carried out using isolated sheep moderator band. Only specimens of a diameter of 1.5 mm or less were used. Each specimen was transferred from the abattoir to the laboratory and inserted in an apparatus designed to measure force-velocity characteristics of heart muscle.
The specimens were perfused with Krebs solution at constant temperature (36.0-36.6°C within a limit of 0.1°C) and constant pH (7.40-7.45 within limits of 0.01 units) for each experiment. The lower end was tied with 5/0 silk to a Kistler 9203 force transducer screwed through the floor of the muscle chamber. The upper end was tied to a movable horizontal arm the other end of which moved a Sanborn 7.DCDT.050 displacement transducer. Specimens were stimulated using a supramaximal 5-msec square wave 12 times per minute.
The output from the Kistler transducer was fed via a charge amplifier to a Tektronix565 oscilloscope which also recorded the output of the Sanbom displacement transducer.
At the start of each experiment the specimen was allowed to stretch under a constant load (preload) of 950 mg which was attached to the end of the horizontal arm. Once full stretch was obtained by each specimen for that load a stop was applied to prevent further stretching, but still allowing shortening. By placing additional loads (afterloads) on the end of the arm extra loads could be applied to the muscle. Recordings were made on 35 mm film of the oscilloscope trace, thus measuring the forces required by the specimen to overcome these afterloads.
Plotting of total load (afterload+preload) against velocity of shortening produced a forcevelocity curve. A direct comparison using the paired t test was done with data obtained at the end of a set control period prior to the drug being given (40 minutes) and at the end of a set period after the drug was given (40 minutes). Further data were obtained after an attempt had been made to 'wash' the drug from the specimen; this was not included in the statistical analysis.
The t tests were done at set loads along the forcevelocity curve. In some cases it was necessary to use interpolated values in the analysis. Concentrations of the drug have been used which relate closely to concentrations found clinically. Using the force-velocity curve as an index the effects of two concentrations of the drug were determined.
At very low concentrations, 0.01 jig/ml, no positive inotropic effect could be demonstrated in 5 specimens. However, at the upper end of the therapeutic range, 0.1 g/ml, a marked positive inotropic effect could be demonstrated which was significant (P<0.025) in 7 specimens. A further 6 specimens were exposed to the high concentration but were first treated with DL- propranolol in a concentration of 0.2 p,g/ml. The positive inotropism was found to be blocked by this dose of propranolol. When used clinically the racemic mixture of pentazocine is used, and therefore further work has been done using the two optical isomers of pentazocine; the levo and the dextro. The force-velocity relationship was again used as an index and five specimens subjected to the levo isomer in a concentration of 0.05 ,ug/ml showed no significant change. However a further 6 specimens subjected to the dextro isomer in the same concentration demonstrated a significant positive inotropic change from the control values. It seemed therefore that the dextro isomer was the one responsible for the myocardial effects. It has been shown in man and animals, such as the rat and pigeon, that the levo isomer is responsible for the analgesic effect.
Conclusions: (1) Pentazocine has a positive inotropic effect on the myocardium. (2) It probably acts via the adrenergic beta receptors.
(3) The dextro isomer is responsible for the effects on the myocardium. (4) In a drug consisting of two isomers, if the unwanted effects reside in the isomer that does not have the therapeutic effects, then these unwanted effects could be eliminated simply by removing the unwanted isomer. Etidocaine is a recently developed amide-type local anesthetic (Adams et al. .1972) . Whilst it bears a structural similarity to lignocaine (Fig 1) , its physical chemical characteristics and its clinical properties are more similar to those of bupivacaine (Table 1) , i.e. high fat solubility, high protein binding and long duration of action (Lund et al. 1973) . It does, however, produce lower blood levels than equimolar doses of bupivacaine and is less toxic (Lund et al. 1973 , Scott et al. 1973 Mean -6.7 + 2. 6 -12.8 -8 block is a useful model in which to study the comparative duration of action of local anesthetic drugs (Simpson et al. 1961 , Ellis et al. 1968 ). This model was used in patients undergoing upper abdominal surgery in an endeavour (1) to establish the concentration of Etidocaine which would abolish pain without producing significant motor block, (2) to establish its duration of action and (3) to compare this duration of action with that of identical concentrations of bupivacaine.
The block was instituted preoperatively in unpremedicated patients. On the first postoperative day equal volumes of Etidocaine 0.375% and 0.5% and of bupivacaine 0.375% and 0.5 % were given in a rotating order unknown to the investigator. Duration of action was assessed by statement by the patient. Motor block was assessed by simple respiratory measurements -forced vital capacity (FVC) and forced expiratory volume in one second (FEV1).
Although the postoperative studies have been completed in only 7 patients, Etidocaine has been used in other patients with upper abdominal wounds and in 8 out of 13 cases Etidocaine 0.375 % has failed to produce adequate analgesia. In these cases Etidocaine 0.5% and both concentrations of bupivacaine were consistently effective, thus implying that Etidocaine is less potent than bupivacaine. The duration of action of the two drugs was broadly comparable, according to the patients' subjective assessment: 0.5% Etidocaine lasted for 85-110 minutes, 0.375% Etidocaine for 75-120 minutes, 0.5%
